Among these genes, our predictions highlight ATF3, JUNB, KLF6, NR4A2, ZFP36, DUSP5, NEDD9, STAT3 and IRF1 as novel and promising upstream regulators of NFκB in prostate cancer, while SELE and the chemokines, including CXCL1 and CXCL2, act as novel downstream targets of NFκB in prostate cancer. This evidence concerns the gene NEDD9 and prostate carcinoma.